Dallas, Texas 11/18/2013 (Financialstrend) – In Friday’s trading session, VIVUS, Inc (NASDAQ:VVUS) rose by 7.54%. The shares opened at a price of $9.15, which touched the intraday high of $9.98 and headed to a close of $9.84. Around 3.30 million exchanged hands over the trading day and an average volume of 2.56 million shares were traded over a 30 day period. The 52-week low of VIVUS, Inc (NASDAQ:VVUS) shares is $8.00 and its 52-week high is $15.62. The company has a market capitalization of $1.00 billion.
About the company
VIVUS, Inc (NASDAQ:VVUS) was incorporated on 16 May 1996. It is a bio-pharmaceutical company. It commercializes & develops various therapies that address unmet-needs in obesity, diabetes, sleep-apnea and sexual health. Qsymia, its drug, is a phentermine & topiramate extended-release formulation. This was approved by the U.S Food and Drug Administration for treatment of obesity as the adjunct to reduced-calorie diet & increased physical-activity for chronic weight-management in adult-patients with an initial BMI of 30 or greater / 27 / greater (overweight) in the presence of at-least 1 weight-related comorbidity, like type 2 diabetes mellitus, hypertension or high cholesterol (dyslipidemia).
Qsymia incorporates low-doses of active ingredients from 2 previously-approved drugs, phentermine & topiramate. VIVUS, Inc (NASDAQ:VVUS) has completed Phase II clinical-studies for Qsymia in the treatment of sleep-apnea. Qsymia is also used for the treatment of type II diabetes. This drug also includes STENDRA / avanafil.
VIVUS, Inc (NASDAQ:VVUS) initially launched Qsymia to be distributed to eligible patients via the home-delivery networks of 2 certified pharmacies, CVS Pharmacy & Walgreens. Since that time, the company has expanded Qsymia’s distribution to include the home-delivery networks of Wal-Mart Pharmacy & Express Scripts, for its members only and Kaiser Permanente. Clinical-studies of topiramate, the component of Qsymia, in type II diabetics resulted in a clinical-reduction of hemoglobin A1c . The Company’s drug, STENDRA, is an oral PDE5-inhibitor that VIVUS, Inc (NASDAQ:VVUS) has now licensed from Mitsubishi Tanabe Pharma Corporation